Medicare covers transcranial magnetic stimulation (TMS) for the treatment of severe major depressive disorder under specific conditions, but there are important exceptions and ongoing costs to consider. Recent updates to coverage rules and costs could impact eligibility and out-of-pocket expenses for beneficiaries.
Understanding Medicare’s coverage for transcranial magnetic stimulation (TMS) is crucial for seniors seeking treatment for severe major depressive disorder. While Medicare does provide coverage under specific conditions, the rules are stricter than many expect, and beneficiaries must navigate various eligibility criteria and potential out-of-pocket costs before proceeding with therapy.
Key Takeaways
- Medicare covers TMS only for severe major depressive disorder when deemed medically necessary.
- TMS treatment is limited to a maximum of 6 weeks, with daily outpatient sessions covered.
- In 2026, Medicare Part B premiums are $202.90, and the annual deductible is $283.
- Beneficiaries may face a 20% coinsurance cost after meeting the deductible for TMS treatment.
- Certain medical conditions, such as seizure disorders and implanted devices, exclude TMS coverage.
- SAINT neuromodulation remains covered under specific CPT codes, maintaining payment stability for 2026.
Related questions people ask
- Does Medicare cover TMS therapy?
- Does Medicare cover TMS therapy for depression?
- How many TMS treatments does Medicare cover?
- Is TMS covered by insurance?
- Is TMS therapy covered by Medicare?
- Is transcranial magnetic stimulation covered by insurance?
- What are the Medicare guidelines for TMS coverage?
- What are the eligibility requirements for TMS coverage under Medicare?
- Are there any restrictions on TMS coverage by Medicare?
- What are the alternatives to TMS therapy?
- How much does TMS therapy cost with Medicare coverage?
- Does Medicare pay for transcranial magnetic stimulation?
Medicare Coverage for TMS Therapy
TMS is Covered for Severe Major Depressive Disorder
Medicare provides coverage for TMS specifically for the treatment of severe major depressive disorder (MDD). This coverage is contingent upon the treatment being deemed medically necessary, ensuring that only those who truly need this intervention receive it. However, it is important to note that Medicare limits TMS coverage to a maximum of 6 weeks of therapy, which includes daily administration of outpatient sessions within that timeframe.
Understanding the Nature of TMS
Transcranial magnetic stimulation (TMS) is a noninvasive therapy that utilizes magnetic fields to stimulate nerve cells in the brain. This innovative procedure is typically performed in an outpatient setting, allowing patients to receive treatment without the need for sedation or anesthesia, making it a convenient option for many.
Updates on TMS Coverage Rules
Recent updates from the Centers for Medicare & Medicaid Services (CMS) have finalized the 2026 Hospital Outpatient Prospective Payment System (OPPS) rule, which preserves the existing payment structure for SAINT neuromodulation, a targeted form of TMS for major depressive disorder. This means that SAINT will continue to be covered under four Category III CPT codes, ensuring that patients have access to this important treatment option.
Understanding Costs Associated with TMS
Medicare Part B Costs for TMS
TMS is generally covered under Medicare Part B as an outpatient service, which is essential for beneficiaries to understand. In 2026, the monthly premium for Medicare Part B is set at $202.90, with an annual deductible of $283. After meeting this deductible, beneficiaries will be responsible for a 20% coinsurance cost for TMS treatment, which can add up depending on the number of sessions required.
Variability in Out-of-Pocket Costs
While Medicare Advantage plans must provide at least the same level of coverage for TMS as Original Medicare, the exact coverage amounts and out-of-pocket costs can vary significantly by plan and location. Additionally, Medigap plans may offer supplemental coverage that helps alleviate some of the out-of-pocket expenses associated with TMS, providing further financial relief for beneficiaries.
Cost Stability for SAINT TMS Therapy
By maintaining the existing Ambulatory Payment Classification (APC) assignments for SAINT, CMS is effectively ensuring that payment rates for this specialized TMS therapy remain stable. However, it is important to note that individual TMS costs under Medicare can still vary based on geographic location and the specific Medicare plan a beneficiary has.
Key Exceptions to TMS Coverage
Medical Conditions Excluding TMS Coverage
There are specific medical conditions that disqualify individuals from receiving Medicare coverage for TMS. For instance, Medicare will not cover TMS for patients who have implanted magnetic-sensitive devices, such as cochlear implants or cardiac defibrillators. Additionally, individuals with seizure disorders or a history of seizures, as well as those exhibiting short-term or long-term psychotic symptoms during their current depressive episode, will also be excluded from coverage.
Neurological Conditions Affecting Eligibility
Certain neurological conditions can further affect eligibility for TMS coverage under Medicare. Conditions such as epilepsy, dementia, and a history of severe head trauma or central nervous system tumors will disqualify individuals from receiving this treatment. It is crucial for potential candidates to be aware of these exclusions when considering TMS as a treatment option.
Clarifications on Coverage Stability
The 2026 OPPS final rule does not introduce a new, broad coverage mandate for TMS; rather, it specifically addresses payment stability for SAINT neuromodulation within hospital outpatient settings. This means that while coverage for SAINT is stable, it may not automatically extend to freestanding non-hospital TMS clinics, which could impact access for some patients.
Eligibility Requirements for TMS Coverage
Diagnosis and Treatment History Requirements
To qualify for Medicare coverage of TMS, individuals must have a confirmed diagnosis of severe major depressive disorder as defined by the DSM-5-TR. Additionally, eligibility requires that patients have undergone one or more trials of pharmacological medication that have failed to alleviate their depressive symptoms, or they must be unable to tolerate psychopharmacologic medications.
Prescribing and Documentation Standards
TMS must be prescribed by a licensed psychiatrist (MD or DO) who has conducted a face-to-face examination of the patient. Furthermore, the psychiatrist is required to review the patient’s mental health records to ensure that all Medicare eligibility requirements for TMS are met before coverage can be applied.
Specifics for SAINT Neuromodulation
SAINT neuromodulation is specifically FDA-cleared for adults with major depressive disorder who have not responded to prior treatments. Medicare’s coverage for SAINT in 2026 aligns with this indication, ensuring that patients who have exhausted other treatment options have access to this innovative therapy.
Recent Updates on TMS Coverage and Costs
Important Changes for 2026
As of 2026, Medicare Part B monthly premiums are set at $202.90, and the annual deductible is $283. Coverage details for TMS were updated on December 3, 2025, reflecting the latest adjustments in Medicare policy.
Stability in Payment Structures
On December 2, 2025, CMS confirmed that payment stability for SAINT neuromodulation would be maintained, ensuring that the Category III CPT codes associated with this treatment will keep their current APC groupings. This stability is crucial for patients and providers alike, as it helps to ensure consistent access to necessary therapies.
Broader Medicare Changes
The broader changes to Medicare in 2026, as outlined in CMS’s final rule, primarily focus on prescription drug coverage adjustments. However, updates regarding TMS coverage and costs have also been highlighted in various industry news articles, emphasizing the importance of staying informed about these developments.
Essential Tips for Navigating TMS Coverage
Verifying Eligibility and Coverage Details
Before pursuing TMS therapy, it is essential for beneficiaries to verify their eligibility requirements, including the necessary diagnosis and medication trials. Additionally, reviewing which part of Medicare applies to TMS costs will help patients understand their financial responsibilities before starting treatment.
Understanding Out-of-Pocket Costs
Beneficiaries should anticipate some out-of-pocket costs for TMS, even when it is covered by Medicare. It is advisable to check specific Medicare plan details to gain a clear understanding of coverage and associated costs, as these can vary significantly.
Planning for SAINT TMS Therapy
When considering SAINT therapy, patients should verify whether the treatment will be delivered in a hospital outpatient setting, as this impacts billing under Medicare. Ensuring that correct documentation is in place for treatment-resistant major depressive disorder is also crucial for a smooth billing process.
Understanding the Implications of TMS Coverage for Seniors
Navigating Medicare coverage for TMS therapy is essential for seniors dealing with severe major depressive disorder, as it is subject to specific conditions and limitations. Beneficiaries should remain aware of ongoing out-of-pocket costs despite coverage, and the confirmed stability in payment structures for SAINT therapy in 2026 offers a sense of reassurance for those seeking effective treatment.
Page content independently curated and maintained by David W. Bynon, Medicare Technical Operator, using a standardized, data-driven methodology designed for accurate, non-commercial Medicare plan interpretation and resolution.